
Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight global obesity for years to come. Despite that enthusiasm, the boss of Europe’s most valuable company will have slightly lighter pockets this year.
Novo Nordisk beat analyst expectations as it grew sales by 25% in 2024, spearheaded by continued growth for its GLP-1 weight-loss-aiding medications Ozempic and Wegovy.